Jubilant Pharmova Ltd.
ISIN: INE700A01033 • Market Cap: ₹13,835 Cr
The 5-Pillar Quality Audit for Jubilant Pharmova Ltd.
Evaluated across Profitability, Financial Health, Historical Compounding, Valuation Safety, and Ownership Governance:
1. Profitability & Capital Efficiency
Weight: 25%Measures operating margins (14.2%), Return on Capital Employed (7.0%), and equity compounding (5.6%).
2. Financial Health & Solvency
Weight: 25%Debt-to-Equity is 0.46 with comfortable interest coverage and clean working capital.
3. Growth & Compounding Track Record
Weight: 20%Historical 3Y Sales CAGR (8.7%) and 3Y PAT CAGR (65.8%).
4. Valuation Multiple & Margin of Safety
Weight: 15%Trades at P/E of 39.29 vs PEG of — and Dividend Yield of 0.6%.
5. Ownership Quality & Governance
Weight: 15%Promoter holding stands at 47.7%, backed by 28.3% institutional ownership.
Key Fundamental Strengths
High-Velocity Profit Compounding (3Y PAT CAGR: 65.8%)
Net earnings have compounded at 65.8% annualized, demonstrating operating leverage.
Deep Institutional Sponsorship (28.3%)
Mutual funds, domestic DIIs, and foreign FIIs hold 28.3%, providing strong governance scrutiny.
Areas to Watch & Potential Risks
Subdued Capital Efficiency (ROCE: 7.0%)
A sub-12% ROCE suggests return on capital barely exceeds the company's weighted average cost of capital (WACC).
Sectoral & Macro Headwinds (Healthcare)
Subject to broader cyclical demand, raw material price shifts, and regulatory frameworks governing the Healthcare space.
Quantitative Strategy Eligibility
Checking JUBLPHARMA against established Indian wealth creation frameworks:
Coffee Can Investing Framework
Fails 10%+ revenue growth or 15%+ minimum capital return benchmark over historical periods.
Quality Factor Screener (High RoIC + Low Debt)
Scorecard of 66/100 or leverage profile sits below strict quality index hurdles.
GARP / Value-Growth Blend
Valuation multiple or return metrics require further cyclical pullback.
Healthcare Sector Peer Comparison
Compare JUBLPHARMA directly against top industry peers by market capitalization:
| Company | 5-Pillar Score | Market Cap | P/E | ROCE | D/E | Scorecard |
|---|---|---|---|---|---|---|
| Jubilant Pharmova Ltd. (JUBLPHARMA)Current | 66/100 | ₹13,835 Cr | 39.29 | 7.0% | 0.46 | — |
| Sun Pharmaceutical Industries Ltd. (SUNPHARMA) | 77/100 | ₹4.55 Lakh Cr | 37.65 | 20.4% | 0.05 | View |
| Divi's Laboratories Ltd. (DIVISLAB) | 73/100 | ₹2.26 Lakh Cr | 77.37 | 19.4% | 0.00 | View |
| Torrent Pharmaceuticals Ltd. (TORNTPHARM) | 64/100 | ₹1.91 Lakh Cr | 87.43 | 9.5% | 1.76 | View |
| Apollo Hospitals Enterprise Ltd. (APOLLOHOSP) | 70/100 | ₹1.27 Lakh Cr | 60.55 | 19.1% | 0.62 | View |
| Cipla Ltd. (CIPLA) | 63/100 | ₹1.14 Lakh Cr | 33.94 | 16.1% | 0.01 | View |
Frequently Asked Questions: Jubilant Pharmova Ltd.
Q:What is the 5-Pillar Fundamental Score for Jubilant Pharmova Ltd. (JUBLPHARMA)?
Jubilant Pharmova Ltd. has a RupeeTools Fundamental Score of 66/100, placing it in the 'Solid & Healthy' category. Its pillar scores are: Profitability (43/100), Financial Health (78/100), Growth (78/100), Valuation (65/100), and Ownership Quality (70/100).
Q:Is JUBLPHARMA fundamentally strong for long-term investment?
JUBLPHARMA currently holds a moderate quality rating of 66/100. While it operates in the Healthcare sector, investors should monitor its profit margins before initiating long-term positions.
Q:Does JUBLPHARMA pass the Coffee Can Investing filter?
No. JUBLPHARMA does not currently meet the strict 15% ROCE and 10% sustained topline compounding threshold mandated by the Coffee Can investing framework.
Q:How does JUBLPHARMA compare against other Healthcare peers?
Within India's Healthcare sector, JUBLPHARMA trades at a P/E of 39.29 and generates an ROCE of 7.0%. Compare its 5-Pillar score of 66/100 against top sector peers like Sun Pharmaceutical Industries Ltd. (77/100), Divi's Laboratories Ltd. (73/100).
Regulatory & SEBI Research Analyst Compliance Disclaimer:
This 5-pillar fundamental score is an automated quantitative health check generated purely from historical public financial statements, corporate filings, and exchange disclosures for educational and informational purposes only. It does NOT constitute investment advice, a stock recommendation, or a solicitation to buy or sell securities. RupeeTools is not a SEBI-registered Research Analyst. Please consult a SEBI-registered financial advisor before making investment decisions.